MDxHealth SA has reported its preliminary financial results for the second quarter of 2025, showing a year-over-year revenue increase of 20%, reaching $26.6 million. The company achieved an adjusted EBITDA profitability of $1.4 million for the quarter. This marks the 17th consecutive quarter of 20% or greater revenue growth for MDxHealth, driven by strong demand for its GPS and Confirm mdx tissue-based tests. The company also announced a definitive agreement to acquire the ExoDx business from Bio-Techne Corporation for $15 million in cash and stock over five years. This acquisition is expected to accelerate revenue growth and be accretive to adjusted EBITDA. The net loss for the quarter was reported at $7.372 million, a 36% improvement from the previous year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.